A genetic tool used to identify thioredoxin as a mediator of a growth inhibitory signal

L P Deiss1, A Kimchi

  • 1Department of Molecular Genetics and Virology, Weizmann Institute of Science, Rehovot, Israel.

Science (New York, N.Y.)
|April 5, 1991
PubMed

Insights

Tumorigenesis involves losing sensitivity to growth inhibitors. Researchers identified human thioredoxin as a key factor in interferon-gamma-mediated growth arrest, crucial for understanding cancer development.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Signaling

Background:

  • Loss of sensitivity to growth inhibitory signals is a hallmark of cancer.
  • Tumorigenesis can arise from disruptions in extracellular signal transduction pathways.
  • Identifying genes involved in growth regulation is critical for understanding cancer formation.

Purpose of the Study:

  • To isolate genes responsible for conferring resistance to growth inhibitory polypeptides.
  • To investigate the role of specific genes in interferon-gamma (IFN-gamma) mediated cellular responses.
  • To identify novel targets for cancer therapy by understanding growth regulation.

Main Methods:

  • Utilized an anti-sense complementary DNA expression library for random gene inactivation.
  • Employed direct selection for cellular growth in the presence of an inhibitory polypeptide.
  • Performed sequence analysis to identify the isolated gene and its function.

Main Results:

  • Successfully isolated a gene whose inactivation conferred resistance to interferon-gamma (IFN-gamma).
  • Sequence analysis revealed the isolated gene to be identical to human thioredoxin.
  • Demonstrated thioredoxin's involvement in the IFN-gamma-mediated growth arrest of HeLa cells.

Conclusions:

  • Human thioredoxin plays a significant role in regulating cellular response to interferon-gamma.
  • Inactivation or loss of thioredoxin function may contribute to tumor formation by disrupting growth inhibitory signals.
  • Thioredoxin emerges as a potential target for therapeutic intervention in cancers associated with IFN-gamma signaling pathways.